Quanterix expands laboratory-developed-test menu with launch of neurofilament light chain test January 11, 2023 -- Quanterix on Monday announced the validation of a laboratory developed test (LDT) to quantitatively measure neurofilament light chain (NfL) in serum as an aid in the evaluation of individuals for possible neurodegenerative conditions or other causes of neuronal or central nervous system damage.Read More
Blood test helps diagnose inaccessible brain tumors January 3, 2023 -- A prospective, blinded study by London’s Imperial College researchers showed the TriNetra-Glio liquid biopsy test, which requires 15 mL of blood, can detect malignant brain tumors.Read More
Study: Menarini’s CellSearch technology effective in measuring and monitoring CTC levels in multiple myeloma December 15, 2022 -- Single-cell technology and liquid biopsy developer Menarini Silicon Biosystems on Wednesday announced results from a study published December 7 in Cancer Discovery demonstrating that the enumeration and genomic characterization of circulating tumor cells (CTCs) at varying stages of multiple myeloma (MM) is invaluable in predicting disease aggressiveness and pathology.Read More
Novel peptide targets Alzheimer’s disease years before symptoms December 12, 2022 -- New research demonstrates a novel synthetic peptide’s ability to selectively detect and neutralize an early molecular trigger of Alzheimer’s disease, with an eye towards early diagnosis and treatment of other amyloid diseases.Read More
AI uncovers molecular mechanism underlying pancreatic cancer December 12, 2022 -- Researchers in Japan have mapped the binding site of the (pro)renin receptor known to be involved in pancreatic cancer development using an artificial intelligence (AI)-based protein structure prediction program.Read More